150 related articles for article (PubMed ID: 37331503)
1. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
2. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
[TBL] [Abstract][Full Text] [Related]
3. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
[TBL] [Abstract][Full Text] [Related]
4. Econazole selectively induces cell death in NF1-homozygous mutant tumor cells.
Lakes YB; Moye SL; Mo J; Tegtmeyer M; Nehme R; Charlton M; Salinas G; McKay RM; Eggan K; Le LQ
Cell Rep Med; 2023 Dec; 4(12):101309. PubMed ID: 38086379
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
[TBL] [Abstract][Full Text] [Related]
6. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
7. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
8. Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.
Mazuelas H; Magallón-Lorenz M; Uriarte-Arrazola I; Negro A; Rosas I; Blanco I; Castellanos E; Lázaro C; Gel B; Carrió M; Serra E
JCI Insight; 2024 Jan; 9(3):. PubMed ID: 38175707
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
10. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
11. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
13.
Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
[TBL] [Abstract][Full Text] [Related]
14. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.
Jiang C; Kumar A; Yu Z; Shipman T; Wang Y; McKay RM; Xing C; Le LQ
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37140985
[TBL] [Abstract][Full Text] [Related]
15. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
16. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
[TBL] [Abstract][Full Text] [Related]
18. Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.
Banerjee J; Allaway RJ; Taroni JN; Baker A; Zhang X; Moon CI; Pratilas CA; Blakeley JO; Guinney J; Hirbe A; Greene CS; Gosline SJ
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098059
[TBL] [Abstract][Full Text] [Related]
19. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
20. P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis.
Patritti Cram J; Wu J; Coover RA; Rizvi TA; Chaney KE; Ravindran R; Cancelas JA; Spinner RJ; Ratner N
Elife; 2022 Mar; 11():. PubMed ID: 35311647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]